PAH is entering a new era of care. Prof Edmund Lau and US expert Prof Jean Elwing sit down to discuss the first-in-class activin signaling inhibitor sotatercept and consider what lies ahead as the next generation of PAH therapies arrives.
Click on the video player control bar to go to specific chapters.
This video was created independently by the limbic. All content was developed by the presenters and views are those of the presenters alone.
Thank you to MSD for providing the unrestricted educational grant that made this project possible.
